Sanofi Strengthens Asian Ambitions with New Chinese Hub and Analyst Backing

Sanofi opens innovation center in Chengdu, upgraded to 'Strong-Buy' by Bernstein. Focus on APAC growth, with China revenue set to rise from 6%.

The French pharmaceutical giant Sanofi is intensifying its strategic focus on the Asia-Pacific region. A clear signal of this commitment was sent with the inauguration of a new innovation center in Chengdu, China, a move promptly endorsed by a bullish upgrade from U.S. analysts.

Analyst Confidence and Strategic Expansion

Market experts at Sanford C. Bernstein responded positively to the company's latest developments, upgrading Sanofi shares to a "Strong-Buy" rating over the weekend. Their rationale highlighted the firm's expanded regional presence and a robust pipeline of future products. This strategic push into Asia is already capital-intensive. Last year alone, approximately one billion euros were allocated to establish an insulin active ingredient production facility in Beijing. Currently, the Chinese market contributes around six percent to Sanofi's total revenue, a share that is expected to grow.

Chengdu Center: A Hub for Integrated Operations

Opened this past weekend, the "China Innovation and Operation Centre" in Sichuan province is designed to consolidate several key functions. It will serve as a centralized location for clinical trials, research initiatives, and supply chain services. The company plans to create up to 600 highly skilled positions at the site by the end of 2026. Management points to the local talent pool and the dynamic biopharma ecosystem in the region as ideal conditions for drug discovery. The Chengdu hub will not operate in isolation but will be closely integrated with Sanofi's existing global centers in countries such as India and Spain.

Financial Stability and Upcoming Catalysts

Beyond geographical growth, Sanofi's share price, recently around 76 euros, is supported by solid financial fundamentals. For 2025, management has proposed a dividend of 4.12 euros, which would mark the 31st consecutive annual increase. This is further complemented by a planned share buyback program of up to one billion euros for the current year. Operationally, the blockbuster drug Dupixent continues to provide a strong foundation, delivering double-digit growth rates. More detailed insights into margin progression and the financial impact of recent investments will be provided on April 23rd, when the company releases its first-quarter results.